Searchable abstracts of presentations at key conferences in endocrinology

ea0081p771 | Late-Breaking | ECE2022

SRSF6 (Serine/arginine-Rich Splicing Factor 6) is a novel factor regulating androgen receptor signalling in prostate cancer cells

Montero-Hidalgo Antonio J. , Manuel Jimenez-Vacas Juan , de la Salud De la Rosa-Herencia Ana , Herrero-Aguayo Vicente , Gomez-Gomez Enrique , Carlos Fuentes-Fayos Antonio , David Gahete-Ortiz Manuel , Miguel Luque-Huertas Raul

Prostate cancer (PCa) represents the most diagnosed tumour pathology in developed countries among men population. The main pharmacological approach to treat this pathology is based on the blockade of the androgen receptor signalling pathway, commonly known as androgen-deprivation therapy. However, some of the patients does no longer respond to this therapy, therefore developing castration-resistant prostate cancer (CRPC), the most aggressive phenotype of this pathology, which ...

ea0090p389 | Endocrine-related Cancer | ECE2023

Therapeutic potential of the splicing factor SRSF6 as a novel regulator of the Androgen Receptor in prostate cancer

Montero-Hidalgo Antonio J. , Gomez-Gomez Enrique , Saez-Martinez Prudencio , Fuentes-Fayos Antonio C. , Sanchez-Sanchez Rafael , Olmos David , Jesus Martinez-Fuentes Antonio , Sarmento-Cabral Andre , Gahete Manuel D. , Manuel Jimenez Vacas Juan , M Luque Raul

Background: Prostate cancer (PCa) is the fifth leading cause of cancer-related death worldwide. The main pharmacological strategy for this pathology is the blockade of the androgen receptor signalling pathway, commonly known as androgen-deprivation therapy. However, some of the patients does no longer respond to this hormonal therapy. Therefore, finding novel therapeutic strategies to tackle PCa, especially its most advanced phenotype [i.e., castration-resistant prostate cance...

ea0041oc9.4 | Endocrine Tumours | ECE2016

The truncated somatostatin receptor sst5TMD4 is overexpressed in prostate cancer, where it increases aggressiveness features by regulating key tumor suppressors and oncogenes.

Hormaechea-Agulla Daniel , Manuel Jimenez-Vacas Juan , Ibanez-Costa Alejandro , Gomez-Gomez Enrique , Carrasco-Valiente Julia , Valero Rosa Jose , Moreno Maria M , Culler Michael D , Gahete Manuel D , Jose Requena Maria , Castano Justo P , Luque Raul M

Somatostatin is a pleiotropic neuropeptide that governs multiple biological targets, including tumor cell function, through a family of G protein-coupled receptors with 7-transmembrane domains (TMD), named sst1-5. However, we recently discovered sst5TMD4, an aberrantly spliced, truncated (only 4-TMDs) sst5-variant displaying unique molecular/functional features. sst5TM4 is overexpressed in various endocrine-related tumors exacerbating their malignant characteristics. Here, we ...